The association of increased blood IGFBP2 with shorter overall survival reported here in lung cancer patients and by others in ovarian cancer, colorectal cancer, and prostate cancer [28,29,31] suggests that IGFBP2 may contribute to malignant evolution and progression. The gene discussed is IGFBP2; the disease is lung cancer.